Program Description:
Allergy/Immunology Grand Rounds is designed so the expected result of our educational activities is that participating physicians enhance their knowledge and skills in the field of Allergy and Clinical Immunology, and apply the knowledge and skills to improve performance and patient outcomes in their Allergy/Asthma/Immunology practice settings.
Our educational activities include department-specific, interdepartmental and specialty-specific conferences of live presentations and live regularly scheduled series. Included among our educational offerings are updates in clinical medicine and basic science research, reviews of current or best practice recommendations for clinical care, learning modules in quality improvement, procedural and communication skills development exercises, as well as professional development in bioethics, leadership and patient safety.
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this Live Activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
Sponsored by the Medical College of Wisconsin, Division of Allergy/Immunology Ranging from 0 - 2500.
Target audience:
Physicians, Physician Assistants, Nurses/Nurse Practitioners, Allied Health Care Professionals, Fellows, Residents, Students
Learning objectives:
Overall Allergy/Immunology Grand Rounds Objectives:
- Adopt new knowledge and updates on Practice Parameters/Guidelines for Allergy/Immunology
- Explore new scientific data improving outcomes for Asthma (decrease in ER visits, hospitalizations, improving quality of life, decreased missed school/work days, etc.) and allergic diseases
- Outline how to improve outcomes in Primary Immune Diseases by learning new scientific developments
Presenter Learning Objectives:
- Define the role that eosinophils may play in various diseases
- Explain how eosinophils are being selectively targeted via novel biological treatments
- Describe the published risks, benefits and outcomes of clinical trials with antibodies directed against interleukin-5 and its receptor.
Faculty & credentials:
Heidi Zafra, MD; Activity Director; No financial relationships to disclose
John Routes, MD; Planning Committee Member; No financial relationships to disclose
Asriani Chiu, MD; Planning Committee Member; No financial relationships to disclose
Brian Kelly, MD; Planning Committee Member; No financial relationships to disclose
Mary Ho, CPNP; Planning Committee Member; No financial relationships to disclose
Bruce Bochner, MD; Speaker; Financial relationships disclosed are as follows:
- I currently serve as a consultant for Sanofi-Aventis and TEVA, and am on the Scientific Advisory Board of Merck and Allakos, Inc.
- I receive publishing royalties from UpToDate and Elsevier.
- I am a co-inventor on existing and pending Siglec-8-related patents. Under a licensing agreement between Allakos, Inc. and the Johns Hopkins University, I am entitled to a share of future royalties received by the University on eventual sales of products described in this presentation. I also own Allakos, Inc. stock, which is subject to certain restrictions under University policy. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
Contact
Session date:
01/17/2014 - 1:15pm to 2:15pm CST
Location:
Allergy/Immunology Clinic, Children's Clinics Building, 4th Floor; Allergy Clinic Teaching Room
9000 W. Wisconsin Avenue
Suite B440
Milwaukee, WI
53226
United States
See map: Google Maps
Add to calendar:
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.